NEW YORK, Sept. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=105586&from=4 CLASS PERIOD: This lawsuit is on beh ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Metagenomi, Inc. stock related to its IPO conducted in February 2024, following the termination of a collaboration agreement with Moderna, which allegedly caused investor damages [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Metagenomi's IPO, where 6.25 million shares were sold at $15 each [5]. - The lawsuit claims that Metagenomi misrepresented its business relationship with Moderna, which was terminated less than three months after the IPO [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by November 25, 2024, to represent other class members [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

Group 1 - A class action lawsuit has been filed against Metagenomi, Inc. in the United States District Court for the Northern District of California on behalf of investors who purchased Metagenomi securities during the initial public offering period from February 9, 2024, to May 1, 2024 [1] - The complaint alleges that Metagenomi made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3] - The company presented itself as a "genetic medicines company" with a significant collaboration with Moderna, claiming a Strategic Collaboration and License Agreement established on October 29, 2021, which included multiple research programs [3]

SAN DIEGO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased stock pursuant to and/or traceable to Metagenomi Inc.'s (NASDAQ: MGX) registration statement for the initial public offering (IPO) held between February 9 and 13, 2024. Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. For more information, ...

Core Viewpoint - A class action lawsuit has been filed against Metagenomi, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors who purchased Metagenomi's securities during its IPO on February 9, 2024, and encourages them to contact the firm before November 25, 2024 [2]. - The lawsuit claims that Metagenomi made false and misleading statements regarding its business relationship with Moderna, which was based on a Strategic Collaboration and License Agreement from October 29, 2021 [4]. Group 2: Impact on Investors - Following the announcement of the termination of the collaboration with Moderna, investors suffered damages as the truth about Metagenomi's misleading public statements was revealed [4].

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ: MGX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Metagenomi ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the stock of Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9 and 13, 2024. For more information, submit a form at Metagenomi, Inc. Shareholder Class Action Lawsuit, email I ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased the securities of Metagenomi Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) between February 9, 2024 and May 1, 2024, both dates inclusive (the "Class Period"). The Complaint alleges that Metagenomi introduced itself to investors during its initi ...

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired stock of Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9 and 13, 2024. You are hereby notified that the class action lawsuit Kevin Vreeland v. Metagenomi, Inc., et al. (Case No. 3:24-cv06765) has been ...

Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a preci ...